These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1909559

  • 1. Pharmacokinetics of encainide in patients with cirrhosis.
    Wensing G, Mönig H, Ohnhaus EE, Hoensch HP.
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559
    [Abstract] [Full Text] [Related]

  • 2. Encainide disposition in patients with chronic cirrhosis.
    Bergstrand RH, Wang T, Roden DM, Avant GR, Sutton WW, Siddoway LA, Wolfenden H, Woosley RL, Wilkinson GR, Wood AJ.
    Clin Pharmacol Ther; 1986 Aug; 40(2):148-54. PubMed ID: 3089668
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and metabolism of encainide.
    Jaillon P.
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT, Thompson KA, Echt DS, Woosley RL, Roden DM.
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
    Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJ, Wilkinson GR.
    J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Encainide disposition in patients with renal failure.
    Bergstrand RH, Wang T, Roden DM, Stone WJ, Wolfenden HT, Woosley RL, Wilkinson GR, Wood AJ.
    Clin Pharmacol Ther; 1986 Jul; 40(1):64-70. PubMed ID: 3087679
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM, Lee JT, Woosley RL, Echt DS.
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [Abstract] [Full Text] [Related]

  • 15. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J, Klein H, Shanks RG, Bender F.
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C, Turgeon J, Woosley RL, Roden DM.
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.